ImmuCell (ICCC) Revenue & Revenue Breakdown
ImmuCell Revenue Highlights
Latest Revenue (Y)
$17.47M
Latest Revenue (Q)
$7.26M
Main Segment (Y)
FirstDefenseProductLineMember
Main Geography (Y)
FirstDefenseProductLineMember
ImmuCell Revenue by Period
ImmuCell Revenue by Year
| Date | Revenue | Change |
|---|---|---|
| 2023-12-31 | $17.47M | -5.90% |
| 2022-12-31 | $18.57M | -3.51% |
| 2021-12-31 | $19.24M | 25.43% |
| 2020-12-31 | $15.34M | 11.80% |
| 2019-12-31 | $13.72M | 24.91% |
| 2018-12-31 | $10.99M | 5.32% |
| 2017-12-31 | $10.43M | 9.29% |
| 2016-12-31 | $9.54M | -6.69% |
| 2015-12-31 | $10.23M | 34.64% |
| 2014-12-31 | $7.60M | 26.46% |
| 2013-12-31 | $6.01M | 11.45% |
| 2012-12-31 | $5.39M | 5.45% |
| 2011-12-31 | $5.11M | 16.53% |
| 2010-12-31 | $4.39M | -2.72% |
| 2009-12-31 | $4.51M | -2.70% |
| 2008-12-31 | $4.63M | -23.65% |
| 2007-12-31 | $6.07M | 26.41% |
| 2006-12-31 | $4.80M | -3.65% |
| 2005-12-31 | $4.98M | 34.82% |
| 2004-12-31 | $3.70M | 10.10% |
| 2003-12-31 | $3.36M | -45.72% |
| 2002-12-31 | $6.18M | -7.37% |
| 2001-12-31 | $6.68M | 18.47% |
| 2000-12-31 | $5.64M | 14.80% |
| 1999-12-31 | $4.91M | 9.09% |
| 1998-12-31 | $4.50M | -2.17% |
| 1997-12-31 | $4.60M | 4.55% |
| 1996-12-31 | $4.40M | -10.20% |
| 1995-12-31 | $4.90M | 11.36% |
| 1994-12-31 | $4.40M | 12.82% |
| 1993-12-31 | $3.90M | - |
ImmuCell generated $17.47M in revenue during NA 2023, up -5.90% compared to the previous quarter, and up 159.04% compared to the same period a year ago.
ImmuCell Revenue by Quarter
| Date | Revenue | Change |
|---|---|---|
| 2024-03-31 | $7.26M | 42.42% |
| 2023-12-31 | $5.10M | -5.57% |
| 2023-09-30 | $5.40M | 52.76% |
| 2023-06-30 | $3.53M | 2.50% |
| 2023-03-31 | $3.45M | -11.87% |
| 2022-12-31 | $3.91M | -18.45% |
| 2022-09-30 | $4.80M | 24.20% |
| 2022-06-30 | $3.86M | -35.64% |
| 2022-03-31 | $6.00M | 10.21% |
| 2021-12-31 | $5.44M | 5.70% |
| 2021-09-30 | $5.15M | 13.39% |
| 2021-06-30 | $4.54M | 10.58% |
| 2021-03-31 | $4.11M | 9.73% |
| 2020-12-31 | $3.74M | 0.55% |
| 2020-09-30 | $3.72M | 25.51% |
| 2020-06-30 | $2.97M | -39.60% |
| 2020-03-31 | $4.91M | 35.20% |
| 2019-12-31 | $3.63M | 22.27% |
| 2019-09-30 | $2.97M | 9.61% |
| 2019-06-30 | $2.71M | -38.56% |
| 2019-03-31 | $4.41M | 50.17% |
| 2018-12-31 | $2.94M | 36.37% |
| 2018-09-30 | $2.15M | -28.55% |
| 2018-06-30 | $3.01M | 4.63% |
| 2018-03-31 | $2.88M | -8.04% |
| 2017-12-31 | $3.13M | 56.26% |
| 2017-09-30 | $2.00M | 14.60% |
| 2017-06-30 | $1.75M | -50.63% |
| 2017-03-31 | $3.54M | 60.08% |
| 2016-12-31 | $2.21M | 12.48% |
| 2016-09-30 | $1.97M | -17.15% |
| 2016-06-30 | $2.38M | -20.45% |
| 2016-03-31 | $2.99M | 10.84% |
| 2015-12-31 | $2.69M | 8.98% |
| 2015-09-30 | $2.47M | 26.12% |
| 2015-06-30 | $1.96M | -36.79% |
| 2015-03-31 | $3.10M | 40.64% |
| 2014-12-31 | $2.21M | 24.58% |
| 2014-09-30 | $1.77M | 14.96% |
| 2014-06-30 | $1.54M | -26.04% |
| 2014-03-31 | $2.08M | 33.51% |
| 2013-12-31 | $1.56M | 26.29% |
| 2013-09-30 | $1.23M | -9.64% |
| 2013-06-30 | $1.37M | -26.00% |
| 2013-03-31 | $1.85M | 29.96% |
| 2012-12-31 | $1.42M | 31.97% |
| 2012-09-30 | $1.08M | -8.37% |
| 2012-06-30 | $1.18M | -31.56% |
| 2012-03-31 | $1.72M | 31.62% |
| 2011-12-31 | $1.30M | 30.01% |
| 2011-09-30 | $1.00M | -19.56% |
| 2011-06-30 | $1.25M | -19.81% |
| 2011-03-31 | $1.56M | 38.82% |
| 2010-12-31 | $1.12M | 28.26% |
| 2010-09-30 | $873.72K | -19.04% |
| 2010-06-30 | $1.08M | -17.75% |
| 2010-03-31 | $1.31M | 26.88% |
| 2009-12-31 | $1.03M | 2.23% |
| 2009-09-30 | $1.01M | 1.03% |
| 2009-06-30 | $1.00M | -31.48% |
| 2009-03-31 | $1.46M | 17.13% |
| 2008-12-31 | $1.25M | 35.04% |
| 2008-09-30 | $924.00K | 11.82% |
| 2008-06-30 | $826.30K | -49.48% |
| 2008-03-31 | $1.64M | 8.84% |
| 2007-12-31 | $1.50M | - |
ImmuCell generated $7.26M in revenue during Q1 2024, up 42.42% compared to the previous quarter, and up 185.57% compared to the same period a year ago.
ImmuCell Revenue Breakdown
ImmuCell Revenue Breakdown by Product
Annual Revenue by Product
| Product/Service | Dec 21 |
|---|---|
| OtherAnimalHealthMember | $309.88K |
| FirstDefenseProductLineMember | $18.93M |
ImmuCell's latest annual revenue breakdown by segment (product or service), as of Dec 21: FirstDefenseProductLineMember (98.39%), and OtherAnimalHealthMember (1.61%).
Quarterly Revenue by Product
| Product/Service | Dec 21 | Sep 21 | Jun 21 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|
| FirstDefenseProductLineMember | $5.40M | $5.03M | $4.47M | - | - |
| OtherAnimalHealthMember | $40.59K | $116.75K | $68.86K | - | - |
| Other Animal Health | - | - | - | $131.06K | $100.32K |
| First Defense Product Line | - | - | - | $2.88M | $2.78M |
ImmuCell's latest quarterly revenue breakdown by segment (product or service), as of Dec 21: FirstDefenseProductLineMember (99.25%), and OtherAnimalHealthMember (0.75%).
ImmuCell Revenue Breakdown by Country
Annual Revenue by Country
| Country | Dec 21 |
|---|---|
| OtherStatesMember | $2.62M |
| UNITED STATES | $16.62M |
| OtherAnimalHealthMember | $309.88K |
| FirstDefenseProductLineMember | $18.93M |
ImmuCell's latest annual revenue breakdown by geography, as of Dec 21: FirstDefenseProductLineMember (49.19%), UNITED STATES (43.19%), OtherStatesMember (6.81%), and OtherAnimalHealthMember (0.81%).
Quarterly Revenue by Country
| Country | Jun 24 | Mar 24 | Sep 23 | Dec 21 | Sep 21 | Jun 21 | Jun 18 | Mar 18 |
|---|---|---|---|---|---|---|---|---|
| UNITED STATES | $4.89M | $6.34M | $4.92M | $4.46M | $4.55M | $4.03M | - | - |
| OtherAnimalHealthMember | - | - | - | $40.59K | - | - | - | - |
| FirstDefenseProductLineMember | - | - | - | $5.40M | - | - | - | - |
| OtherStatesMember | - | - | - | $984.57K | $599.83K | $511.57K | - | - |
| Other States | - | - | - | - | - | - | $470.41K | $285.57K |
| United States | - | - | - | - | - | - | $2.54M | $2.60M |
ImmuCell's latest quarterly revenue breakdown by geography, as of Jun 24: UNITED STATES (100.00%).
ImmuCell Peer Comparison by Revenue
| Ticker | Company | Last Year Revenue | Last Quarter Revenue |
|---|---|---|---|
| LIPO | Lipella Pharmaceuticals | $449.62M | $136.43M |
| FENC | Fennec Pharmaceuticals | $21.64M | $25.26M |
| ICCC | ImmuCell | $17.47M | $7.26M |
| HCWB | HCW Biologics | $2.84M | $618.85K |
| MNOV | MediciNova | $1.00M | - |
| ANEB | Anebulo Pharmaceuticals | - | - |
| RZLT | Rezolute | - | - |
| CYT | Cyteir Therapeutics | - | - |
| ELYM | Eliem Therapeutics | - | - |
| CVKD | Cadrenal Therapeutics | - | - |
| TPST | Tempest Therapeutics | - | - |
| PTIX | Protagenic Therapeutics | - | - |
ICCC Revenue FAQ
What is ImmuCell’s yearly revenue?
ImmuCell's yearly revenue for 2023 was $17.47M, representing a decrease of -5.90% compared to 2022. The company's yearly revenue for 2022 was $18.57M, representing a decrease of -3.51% compared to 2021. ICCC's yearly revenue for 2021 was $19.24M, representing an increase of 25.43% compared to 2020.
What is ImmuCell’s quarterly revenue?
ImmuCell's quarterly revenue for Q1 2024 was $7.26M, a 42.42% increase from the previous quarter (Q4 2023), and a 110.58% increase year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $5.1M, a -5.57% decrease from the previous quarter (Q3 2023), and a 30.30% increase year-over-year (Q4 2022). ICCC's quarterly revenue for Q3 2023 was $5.4M, a 52.76% increase from the previous quarter (Q2 2023), and a 12.52% increase year-over-year (Q3 2022).
What is ImmuCell’s revenue growth rate?
ImmuCell's revenue growth rate for the last 3 years (2021-2023) was -9.20%, and for the last 5 years (2019-2023) was 27.32%.
What are ImmuCell’s revenue streams?
ImmuCell's revenue streams in c 21 are OtherAnimalHealthMember, and FirstDefenseProductLineMember. OtherAnimalHealthMember generated $309.88K in revenue, accounting 1.61% of the company's total revenue FirstDefenseProductLineMember generated $18.93M in revenue, accounting 98.39% of the company's total revenue
What is ImmuCell’s main source of revenue?
For the fiscal year ending Dec 21, the largest source of revenue of ImmuCell was FirstDefenseProductLineMember. This segment made a revenue of $18.93M, representing 98.39% of the company's total revenue.